Patterns of outpatient antihypertensive medication use during pregnancy in a medicaid population

Hypertension

Volumn 60, Issue 4, 2012, Pages 913-920

  Bateman, Brian T ^a,b   Hernandez Diaz, Sonia ^c   Huybrechts, Krista F ^a   Palmsten, Kristin ^c   Mogun, Helen ^a   Ecker, Jeffrey L ^b   Fischer, Michael A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

antihypertensives; epidemiology; hypertension; pregnancy

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LABETALOL; METHYLDOPA;

ADOLESCENT; ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CHILD; COHORT ANALYSIS; DELIVERY; DIABETES MELLITUS; ENVIRONMENTAL EXPOSURE; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; INFANT; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MEDICAID; MENSTRUAL CYCLE; OUTPATIENT; PREGNANCY; PRIORITY JOURNAL; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY;

ADOLESCENT; ADULT; AGE FACTORS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DRUG UTILIZATION; FEMALE; HUMANS; HYPERTENSION, PREGNANCY-INDUCED; MEDICAID; MIDDLE AGED; OUTPATIENTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; UNITED STATES;

EID: 84866540021     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.197095     Document Type: Article

References (33)

1. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classifcation and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001;20:IX-XIV.
2. Kuklina EV, Ayala C, Callaghan WM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol. 2009;113:1299-1306.
3. Report of the national high blood pressure education program working group on high blood pressure in pregnancy. Am J Obstet Gynecol. 2000;183:S1-S22.
4. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002;99:159-167.
5. ACOG practice bulletin. Chronic hypertension in pregnancy. ACOG committee on practice bulletins. Obstet Gynecol. 2001;98:177-185.
6. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007:CD002252.
7. de Swiet M. Maternal blood pressure and birthweight. Lancet. 2000;355:81-82.
8. Tabacova S, Kimmel CA, Wall K, Hansen D. Atenolol developmental tox-icity: animal-to-human comparisons. Birth Defects Res Part A Clin Mol Teratol. 2003;67:181-192.
9. Källén BA, Otterblad Olausson P. Maternal drug use in early pregnancy and infant cardiovascular defect. Reprod Toxicol. 2003;17:255-261.
10. Cooper WO, Hernandez-Diaz S, Arbogast PG, Dudley JA, Dyer S, Gideon PS, Hall K, Ray WA. Major congenital malformations after frst-trimester exposure to ACE inhibitors. N Engl J Med. 2006;354:2443-2451.
11. Lennestål R, Otterblad Olausson P, Källén B. Maternal use of antihyper-tensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol. 2009;65:615-625.
12. Caton AR, Bell EM, Druschel CM, Werler MM, Lin AE, Browne ML, McNutt LA, Romitti PA, Mitchell AA, Olney RS, Correa A; National Birth Defects Prevention Study. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension. 2009;54:63-70.
13. Nakhai-Pour HR, Rey E, Bérard A. Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns. Birth Defects Res B Dev Reprod Toxicol. 2010;89:147-154.
14. Davis RL, Eastman D, McPhillips H, Raebel MA, Andrade SE, Smith D, Yood MU, Dublin S, Platt R. Risks of congenital malformations and perinatal events among infants exposed to calcium channel and beta-blockers during pregnancy. Pharmacoepidemiol Drug Saf. 2011;20:138-145.
15. Li DK, Yang C, Andrade S, Tavares V, Ferber Jr. Maternal exposure to angiotensin converting enzyme inhibitors in the frst trimester and risk of malformations in offspring: a retrospective cohort study. BMJ. 2011;343:d5931.
16. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
17. Seely EW, Ecker J. Clinical practice. Chronic hypertension in pregnancy. N Engl J Med. 2011;365:439-446.
18. Magee LA, Helewa M, Moutquin JM, von Dadelszen P; Hypertension Guideline Committee; Strategic Training Initiative in Research in the Reproductive Health Sciences (STIRRHS) Scholars. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. J Obstet Gynaecol Can. 2008;30(3 Suppl):S1-48.
19. Brown MA, Hague WM, Higgins J, Lowe S, McCowan L, Oats J, Peek MJ, Rowan JA, Walters BN; Austalasian Society of the Study of Hypertension in Pregnancy. The detection, investigation and management of hypertension in pregnancy: full consensus statement. Aust N Z J Obstet Gynaecol. 2000;40:139-155.
20. Andrade SE, Raebel MA, Brown J, Lane K, Livingston J, Boudreau D, Rolnick SJ, Roblin D, Smith DH, Dal Pan GJ, Scott PE, Platt R. Outpatient use of cardiovascular drugs during pregnancy. Pharmacoepidemiol Drug Saf. 2008;17:240-247.
21. Markus AR, Rosenbaum S. The role of Medicaid in promoting access to high-quality, high-value maternity care. Womens Health Issues. 2010;20 (1 Suppl):S67-S78.
22. Palmsten K, Huybrechts K, Mogun H, Setoguchi S, Hernandez-Diaz S. Medicaid analytic extract for studies of drug safety during pregnancy [abstract]. Pharmacoepidemiol Drug Safety 2011;20:S266.
23. Margulis AV, Setoguchi S, Mittleman MA, Glynn RJ, Dormuth CR, Hernández-Díaz S. Algorithms to estimate the beginning of pregnancy in administrative databases. Pharmacoepidemiol Drug Saf. May 2, 2012. DOI: 10.1002/pds.3284. http://onlinelibrary.wiley.com/doi/10.1002/pds.3284/full. Accessed August 23, 2012.
24. Podymow T, August P. Update on the use of antihypertensive drugs in pregnancy. Hypertension. 2008;51:960-969.
25. Sibai BM, Grossman RA, Grossman HG. Effects of diuretics on plasma volume in pregnancies with long-term hypertension. Am J Obstet Gynecol. 1984;150:831-835.
26. Bateman BT, Bansil P, Hernandez-Diaz S, Mhyre JM, Callaghan WM, Kuklina EV. Prevalence, trends, and outcomes of chronic hypertension: a nationwide sample of delivery admissions. Am J Obstet Gynecol. 2012;206:134.e1-134.e8.
27. Kim SY, Dietz PM, England L, Morrow B, Callaghan WM. Trends in pre-pregnancy obesity in nine states, 1993-2003. Obesity (Silver Spring). 2007;15:986-993.
28. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Mathews TJ, Kirmeyer S, Osterman MJ. Births: Final data for 2007. Natl Vital Stat Rep. 2010;58:1-85.
29. Klemmensen AK, Olsen SF, Osterdal ML, Tabor A. Validity of pre-eclampsia-related diagnoses recorded in a national hospital registry and in a postpartum interview of the women. Am J Epidemiol. 2007;166:117-124.
30. Bullano MF, Kamat S, Willey VJ, Barlas S, Watson DJ, Brenneman SK. Agreement between administrative claims and the medical record in identifying patients with a diagnosis of hypertension. Med Care. 2006;44:486-490.
31. Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF. Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care. 2005;43:480-485.
32. Nassar AH, Aoun J, Usta IM. Calcium channel blockers for the management of preterm birth: a review. Am J Perinatol. 2011;28:57-66.
33. Fenstermacher N, Levin M, Ward T. Pharmacological prevention of migraine. BMJ. 2011;342:d583.